

# MM24

## Molecular Methods for Genotyping and Strain Typing of Infectious Organisms

This guideline examines the biology behind molecular strain typing and genotyping, as well as characterization and validation of these systems. It also provides recommendations regarding criteria to be considered for design, validation, and determination of clinical utility of such testing.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Molecular Methods for Genotyping and Strain Typing of Infectious Organisms

Ted E. Schutzbank, PhD, D(ABMM)  
Sherry A. Dunbar, PhD, MBA  
Tabetha Sundin, PhD  
Kimberly M. Anderson, PhD  
Esther Babady, PhD, D(ABMM)  
George Broukhanski, PhD  
Sanchita Das, MD, D(ABMM)

David L. Dolinger, PhD  
Peera Hemarajata, MD, PhD, D(ABMM),  
PHM, CLS, M(ASCP)<sup>CM</sup>  
Awdhesh Kalia, PhD, MB(ASCP)<sup>CM</sup>, FACSc  
Dylan Pillai, MD, PhD, FRCPC  
Astrid Schroeder, PhD

## Abstract

Molecular genotyping and strain typing are essential tools for the analysis of infectious etiological agents of human diseases isolated during investigations of epidemiological outbreaks, laboratory contamination, and recurrent infection. A wide variety of genotyping and strain typing methods have been described using contemporary nucleic acid–based technologies. These methods are used for identifying virulence factors, drug resistance, markers of disease progression within an institution or a community, and in certain cases, patient prognosis. Clinical and Laboratory Standards Institute guideline MM24—*Molecular Methods for Genotyping and Strain Typing of Infectious Organisms* examines the biology behind molecular genotyping and strain typing and the process of characterizing and validating typing systems. The prevalent methods currently being used in laboratories that perform genotyping and strain typing include nucleic acid amplification tests, ribotyping, sequence-based typing (Sanger and next-generation sequencing), hybridization-based typing methods (microarrays, line-probe arrays), molecular fingerprinting (pulse-field gel electrophoresis, restriction fragment-length polymorphism analysis, multiple locus variable–number of tandem repeat analysis), and protein-based typing. Each of these areas is described in detail specific to the genotyping and strain typing of nucleic acid in clinical testing and monitoring, particularly in bacterial, fungal, and viral diseases. This guideline also includes an update on technologies used for molecular genotyping and strain typing, sample preparation, standards, calibrators, reference materials, analytical and clinical verification/validation, reporting and interpreting results, and clinical utility.

Clinical and Laboratory Standards Institute (CLSI). *Molecular Methods for Genotyping and Strain Typing of Infectious Organisms*. 1st ed. CLSI guideline MM24 (ISBN 978-1-68440-126-0 [Print]; ISBN 978-1-68440-127-7 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2021.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2021 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Molecular Methods for Genotyping and Strain Typing of Infectious Organisms*. 1st ed. CLSI guideline MM24. Clinical and Laboratory Standards Institute; 2021.

### Previous Editions:

MM10 (withdrawn): March 2005, February 2006

MM11: May 2006, April 2016 (reaffirmed), January 2017 (archived)

MM24-Ed1

ISBN 978-1-68440-126-0 (Print)

ISBN 978-1-68440-127-7 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 41, Number 19

# Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Scope .....	2
1.2 Background .....	2
1.3 Standard Precautions .....	9
1.4 Terminology .....	10
<b>Chapter 2: Path of Workflow .....</b>	<b>25</b>
2.1 Process Flow Chart .....	26
2.2 Specimen Collection and Handling .....	27
<b>Chapter 3: Genotyping and Molecular Strain Typing Methods .....</b>	<b>29</b>
3.1 Nucleic-Acid Amplification Test–based Typing .....	30
3.2 Sequencing-based Typing .....	41
3.3 Hybridization-based Typing .....	48
3.4 Molecular Fingerprinting Techniques .....	53
3.5 Protein-based Typing (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry) .....	60
<b>Chapter 4: Standards, Controls, and Reference Materials .....</b>	<b>65</b>
4.1 Standards .....	66
4.2 Controls .....	68
<b>Chapter 5: Validation and Verification .....</b>	<b>73</b>
5.1 Validation .....	74
5.2 Verification .....	75
<b>Chapter 6: Interpreting and Reporting Data .....</b>	<b>85</b>
6.1 Clinical and Epidemiological Applications .....	86
6.2 Genotyping and Strain Typing Bioinformatics .....	90

## Contents (Continued)

<b>Chapter 7: Quality System Essentials</b> .....	<b>95</b>
7.1 Organization and Leadership .....	96
7.2 Customer Focus .....	96
7.3 Facilities and Safety Management .....	97
7.4 Personnel Management .....	98
7.5 Supplier and Inventory Management .....	98
7.6 Equipment Management .....	98
7.7 Process Management .....	99
7.8 Documents and Records Management .....	100
7.9 Information Management .....	101
7.10 Nonconforming Event Management .....	101
7.11 Assessments .....	102
7.12 Continual Improvement .....	102
<b>Chapter 8: Conclusion</b> .....	<b>103</b>
<b>Chapter 9: Supplemental Information</b> .....	<b>105</b>
<b>References</b> .....	106
<b>Additional Resources</b> .....	132
<b>Appendix A.</b> Form for Triaging and Submitting Referral Specimens for Genotyping and Strain Typing .....	133
<b>Appendix B.</b> Strain Typing and Genotyping Methods .....	134
<b>Appendix C.</b> Sample Bacterial Strain Typing Report .....	144
<b>Appendix D.</b> Commonly Used Software and Web-based Platforms to Perform Bacterial and Virus Genotyping Using High-Throughput DNA Sequencing Data .....	147
<b>The Quality Management System Approach</b> .....	162
<b>Related CLSI Reference Materials</b> .....	163

## Foreword

When CLSI documents MM10 and MM11 were published in 2006 and 2007, respectively, nucleic acid testing methods used for genotyping and strain typing, although partially overlapping, were somewhat different in scope. As such, CLSI document MM10 (which has since been withdrawn from CLSI's library) described genotyping, whereas CLSI document MM11 focused on strain typing. In the intervening years, applications introduced for performing this testing have resulted in greater similarity between genotyping in the classical sense and strain identification. These genomic approaches have allowed a growing number of medical laboratories to perform this testing without differentiating between genotyping and strain identification. This guideline reflects the technological advances made in this field and encompasses genotyping, genomic identification, and strain identification of all types of infectious diseases agents.

### Overview of Changes

This guideline replaces the previous edition of the approved guideline, MM11-A, published in 2007. MM24 also builds on topics introduced in CLSI document MM10, published in 2006, which has since been withdrawn from CLSI's library. Several changes were made in this edition, including:

- Adding a process flow chart showing the basic steps that are followed to perform genotypic and strain typing of infectious organisms
  - Each step in the process is mapped to the relevant section in this guideline.
- Providing detailed descriptions on how genotyping and strain typing are used in different settings, in particular, genotyping and strain typing in the clinical setting vs epidemiological applications of genotyping and strain typing of infectious organisms
- Updating information on the current technologies used for genotyping and strain typing
  - Discussion of technologies that are no longer used and/or have been replaced by newer methods has been eliminated.
- Providing detailed descriptions of the quality system essentials that are relevant for laboratories that perform genotyping and/or strain typing of infectious organisms
- Adding appendixes that provide example forms used in genotyping and strain typing, additional details on various technologies, and information on relevant software and Web-based applications

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

#### KEY WORDS

5'-nuclease

Association studies

Bioinformatics

Genotyping

Linkage disequilibrium

Linkage mapping

Oligonucleotide ligation assay

Single-nucleotide  
polymorphism

Strain typing

Whole genome sequencing

Uses of Illumina®, PacBio®, and SMRT® Link in this guideline are not endorsements on the part of CLSI.

# Chapter 1

## Introduction

### This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- Terminology information, including:
  - Terms and definitions used in the guideline
  - Abbreviations and acronyms used in the guideline

Sample

# Molecular Methods for Genotyping and Strain Typing of Infectious Organisms

---

## 1 Introduction

### 1.1 Scope

This guideline provides a framework for facilitating consistency in reporting genotypes and bacterial, viral, and fungal strain typing and will assist laboratories that perform these studies and the professionals applying the results. Its purpose is to present not only the technologies used but also the criteria to be considered for design, verification, validation, and determination of clinical utility of such testing. These technologies are now used in many different contexts, including:

- Clinical care settings
- Public health investigations, particularly of emerging infections
- Food and pharmaceutical industries
- Environmental analyses in the clinical setting
- Regulatory agencies

This guideline is intended for manufacturers or laboratories that develop assays, laboratories that perform assays, clinicians who use the results to diagnose or manage patients, and agencies that regulate their use. This guideline:

- Is not intended for use by research laboratories
- Is not intended to provide manufacturing guidelines
- Does not discuss the development of standard reference materials for QC use

It is recommended that this guideline be used in conjunction with CLSI documents MM03,<sup>1</sup> MM06,<sup>2</sup> MM09,<sup>3</sup> MM12,<sup>4</sup> MM13,<sup>5</sup> MM14,<sup>6</sup> MM17,<sup>7</sup> MM18,<sup>8</sup> and MM22.<sup>9</sup>

### 1.2 Background

The expanding use of molecular testing methods has enabled laboratories to characterize features of infectious agents that not only affect patient care and disease course but also allow epidemiologists to track organisms throughout the population. Genome analysis of some viruses, bacteria, and other organisms may identify variants, genes, and gene functions that have clinical effects such as patient prognosis, disease progression, and management of patient drug therapy. This information is also used epidemiologically and by regulatory agencies for surveillance, outbreak investigations, and population genetics.

Recent advances in the field of molecular diagnostic methods have enabled the expanded use of molecular genotyping and strain typing to better understand the genetics associated with pathogen gene functions and their relationship to virulence, attenuation, disease progression, and prognosis during infection, as well as drug resistance. The choice of assay format and technology platform continues to be dictated by the complexity of genetic information needed. This guideline provides recommendations for the development, verification, validation, and implementation of clinical molecular tests for genotyping or strain typing for laboratories and manufacturers. It was written during a period of prolific expansion of molecular techniques applicable to genotype and strain type testing and includes technologies in practical clinical use at the time of publication.



## 2 Path of Workflow


### 2.1 Process Flow Chart

Figure 2 shows the steps involved in genotyping and molecular strain typing, from specimen collection and handling to analysis and interpretation of results.




<sup>a</sup>Three basic symbols are used in this process flow chart: oval (signifies the beginning or end of a process), arrow (connects process activities), box (designates process activities).

**Figure 2. Genotyping and Strain Typing Process<sup>a</sup>**



**Figure 9. Ribotype Pattern of Three Different *C. difficile* Isolates Using Capillary Electrophoresis.** Panels A through C represent three different isolates. In each panel, the y-axis shows the fluorescent intensity and the x-axis shows the length of the PCR product in bp. Blue peaks represent the fragments generated by PCR, and the orange peaks are size standards. The total number of peaks, along with their height and their length, determine the PCR ribotype. Panels B and C show isolates belonging to the same ribotype (ribotype 449).




**Figure 10. Ribotype Pattern Using Agarose Gel Electrophoresis.** The virtual image is generated using a statistical algorithm that also produces a dendrogram. Lanes 6 through 8 and lanes 9 through 11 show isolates that belong to the same ribotype.

# Discover How CLSI Can Improve Your Organization



*The leading source for the latest medical laboratory standards.*



CLSI membership lets you directly impact best practice standards used to improve patient care worldwide—standards you use every day. Membership provides you with standards access, volunteering opportunities, influence in the standards development process, networking opportunities, discounts, and more.

Discover the membership option for you at [clsi.org/join](https://clsi.org/join).



Our educational and training programs provide convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources and in-person trainings that make learning stress-free and convenient for you and your staff.

See our current offerings at [clsi.org/global-training](https://clsi.org/global-training).



Ensure high-quality laboratory testing with CLSI standards. eCLIPSE Ultimate Access™, our complete online library of standards, makes it easy for you and your staff to quickly find the CLSI resources you need. Read, search, link, annotate, bookmark, and share notes with your staff, all within one easy-to-use platform.

Learn more at [clsi.org/eCLIPSE](https://clsi.org/eCLIPSE).

# Sample



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

PRINT ISBN 978-1-68440-126-0

ELECTRONIC ISBN 978-1-68440-127-7

MM24-Ed1